Adjuvant therapy in melanoma

Clinical and Experimental Dermatology

Volumn 25, Issue 6, 2000, Pages 497-502

  Whittaker, S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CISPLATIN; DACARBAZINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 2; LEVAMISOLE; TAMOXIFEN;

ADOPTIVE IMMUNOTHERAPY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; PROGNOSIS;

EID: 0033774195     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2000.00704.x     Document Type: Review

References (29)

1. Recognition of human melanoma ceils by HLA-A2.1 restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes
2. Classification and staging
3. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma
4. Technical details of intraoperative lymphatic mapping for early stage melanoma
5. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma
6. Outcome of patients with melanoma and histologically negative sentinel lymph nodes
7. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
8. Molecular staging of malignant melanoma. Correlation with clinical outcome
9. Adjuvant BCG immunotherapy for malignant melanoma
10. A randomised trial of levamisole versus placebo as adjuvant therapy in malignant melanoma
11. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin: A phase III adjuvant study
12. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease
13. Interferons: Biochemical, cell growth, inhibitory and immunological effects
14. Interferons in the treatment of cancer
15. Interferon α-2a therapy for life threatening haemangiomas of infancy
16. Randomized, surgical adjuvant clinical trial of recombinant interferon α-2a in selected patients with malignant melanoma
17. Interferon α-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
18. Quality of life adjusted survival analysis of interferon alfa-2b treatment of high risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
19. Economic analysis of adjuvant interferon α-2b in high risk melanoma based on projections from Eastern Cooperative Oncology Group 1684
20. Evaluation of efficacy of adjuvant rIFN α-2a in melanoma patients with regional node metastasis
21. Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma
22. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastasis
23. Efficacy of elective regional lymph node dissection of 1-4mm thick melanomas for patients 60 years of age and younger
24. Systemic treatment for advanced cutaneous melanoma
25. Use of tumour infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastaic melanoma
26. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon α-2b
27. Multi-institutional phase 11 trials of intensive combination chemoimmunotherapy for metastatic melanoma